HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Metalpha Technology Holding Limited (Nasdaq: MATH) ("Metalpha" or the "Company"), a global leading provider of blockchain and trading technology solutions, today announced that its Board of Directors has adopted a BTC allocation plan up to 20% of the Company's annual net profit. For the current period, the authorized allocation quota is approximately US$3.2 million, 20% of the Company's net profit of US$15.9 million as reported in its Annual Report on Form 20-F for t ...

CALGARY, Alberta, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Maxim Power Corp. ("MAXIM" or the "Corporation") (TSX: MXG) announces that it has entered into a gas turbine and generator reservation agreement (the “Agreement”) with GE Vernova (NYSE: GEV). The Agreement allows MAXIM to hold a manufacturing slot for a 7HA.02 gas turbine and generator package (the “Gas Turbine”) with a target delivery by 2030. To hold this manufacturing slot, MAXIM is required to provide a non-refundable deposit which is payable in 2026. ...

While making a mistake with your finances is common, what’s less common is having someone else take advantage of your slip-up. But Americans should be aware of the risks, especially as reports of fraud are on the rise. The Federal Trade Commission reports that in 2023, only 27% of people who reported fraud said they lost money. In 2024, that figure jumped to 38% (1). The overall cost: $12.5 billion. Must Read Fraud can happen in the most ordinary circumstances. Take Christl. She recently moved to a dif ...

Core Viewpoint - Novo Nordisk is suing Hims & Hers for marketing unapproved copies of its Wegovy obesity drug, claiming it deceives patients and poses health risks due to lack of regulatory verification [1][2][7]. Group 1: Legal Actions and Claims - Novo is seeking a permanent ban on Hims from selling compounded versions of its drugs that infringe on patents and is pursuing damages [2]. - Hims announced it would stop offering its copycat obesity pill after facing scrutiny from regulators and legal threats from Novo [3]. - The FDA plans to take legal action against Hims, including restricting access to ingredients and referring the company to the Department of Justice for potential violations [8]. Group 2: Market Context and Competition - The lawsuit occurs as Novo aims to reclaim market share in the growing obesity drug market, facing competition from Eli Lilly and compounded alternatives [4]. - Novo has increased manufacturing capacity, eliminating shortages of semaglutide, the active ingredient in Wegovy, which has seen a successful launch since January [5]. - Despite the lack of shortages, an estimated 1.5 million Americans are using compounded GLP-1 drugs, indicating a significant market for alternatives [5]. Group 3: Regulatory and Safety Concerns - Hims claims its compounded products are legal due to personalized dosages, despite semaglutide being protected by U.S. patents until 2032 [6]. - Novo argues that Hims is engaging in illegal mass compounding, undermining safety and efficacy standards established by the FDA [7]. - The aggressive legal actions by Novo and Lilly against compounding pharmacies reflect the rising popularity of their weight loss and diabetes drugs [9].

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Westhaven Gold Corp. (TSX-V: WHN) (OTCQB: WTHVF) (“Westhaven” or the “Company”) is pleased to announce that the Company's stock will commence trading on the OTCQB Venture Market (“OTCQB”), effective today, February 9, 2026, under the symbol "WTHVF". Ken Armstrong, President & CEO of Westhaven, commented, “Listing Westhaven on the OTCQB increases our visibility and enhances trading accessibility for U.S. investors, providing a more efficient way ...

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbo ...

Group 1: Hims & Hers Health (HIMS) - Hims & Hers Health announced it will stop offering a compounded version of Novo Nordisk's Wegovy pill due to pressure from Novo and increased FDA scrutiny [3][4] - Following this announcement, HIMS shares fell by 15% in premarket trading [2] Group 2: Samsung Electronics (SSNLF) - Samsung Electronics' shares rose by 6.4% after reports of imminent mass production of HBM4 memory chips, which are essential for AI infrastructure [4] - The company plans to ship these semiconductors to Nvidia as early as the third week of February [5] Group 3: Luckin Coffee (LKNCY) - Luckin Coffee inaugurated its 30,000th store, marking a shift towards targeting Starbucks' premium market with its first flagship store in Shenzhen [5][6] - The flagship store features higher-priced offerings compared to typical Luckin products, with a focus on pour-over and cold brew coffee drinks [7] - This store also represents Luckin's first use of high-end semi-automatic coffee machines [7]

West Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Surge Battery Metals Inc. (TSXV: NILI) (OTCQX: NILIF) (FSE: DJ5C) (the "Company" or "Surge") is pleased to announce that Nevada North Lithium LLC (NNL), the joint venture formed by Surge and Evolution Mining Limited (Evolution) has selected Fluor Enterprises, Inc. ("Fluor") as the lead engineering firm to lead the Pre-Feasibility Study ("PFS") at its flagship Nevada North Lithium Project ("NNLP").The selection of Fluor, one of the worl ...

A seven-figure retirement portfolio may seem like an unshakeable safety net, but in practice, it can be fragile. People are living longer than ever, healthcare costs are rising sharply, inflation remains persistently high and a few overlooked spending habits can erode even a $1 million portfolio over time. Must Read Here are three critical mistakes that millionaire retirees make that can jeopardize their financial security. 1. Not planning for long-term care Although every senior wants to stay in th ...

Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that inf ...